drugset
drugset / Trial / NCT04766385

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

NCT04766385 ↗

Phase 3 Completed 54 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those receiving placebo.

Timeline

Start
2021-03-03
Primary completion
2021-12-01
Completion
2021-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 5 mg Oral
Subject Tenapanor Small molecule 10 mg Oral
Subject Tenapanor Small molecule 20 mg Oral
Subject Tenapanor Small molecule 30 mg Oral

Indications

hyperphosphatemia